ZYLM (Central Asia Lumeichun Biotechnology) Marketable Securities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Central Asia Lumeichun Biotechnology Marketable Securities?

Central Asia Lumeichun Biotechnology ZYLM Marketable Securities is $0.00 Mil as of Jun. 2026.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Central Asia Lumeichun Biotechnology's Marketable Securities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Central Asia Lumeichun Biotechnology's annual Marketable Securities stayed the same from Aug. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil) but then declined from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.00 Mil).

Central Asia Lumeichun Biotechnology  (OTCPK:ZYLM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Central Asia Lumeichun Biotechnology Marketable Securities Related Terms

Central Asia Lumeichun Biotechnology Marketable Securities Historical Data

* Premium members only.

The historical data trend for Central Asia Lumeichun Biotechnology's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology Marketable Securities Chart

Central Asia Lumeichun Biotechnology Annual Data
Trend Mar07 Mar08 Mar09 Mar10 Mar11 Mar14 Mar15 Aug23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.01 0.01 0.00

Central Asia Lumeichun Biotechnology Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun13 Jun15 Sep15 Dec15 Nov22 Feb23 May23 Aug23 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

Central Asia Lumeichun Biotechnology Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Central Asia Lumeichun Biotechnology (ZYLM) has a Marketable Securities of $0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Central Asia Lumeichun Biotechnology and its competitors.
Is Central Asia Lumeichun Biotechnology's Marketable Securities too high?
Central Asia Lumeichun Biotechnology's current Marketable Securities is $0.00 Mil.
How does Central Asia Lumeichun Biotechnology's Marketable Securities compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's Marketable Securities of $0.00 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Consumer Packaged Goods company?
A good Marketable Securities depends on the Consumer Packaged Goods industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Central Asia Lumeichun Biotechnology and its competitors. Central Asia Lumeichun Biotechnology's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current Marketable Securities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Asia Lumeichun Biotechnology Business Description

Address Longguan Avenue, Room 1401, Yunhua Building, Longhua District, Shenzhen, CHN
Central Asia Lumeichun Biotechnology Inc is an ecological agriculture company. It operates a sika deer breeding base in southern China.